Cancer Stem Cells - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cancer stem cells market size was valued at USD 2.63 billion in 2025 and estimated to grow from USD 2.93 billion in 2026 to reach USD 5.07 billion by 2031, at a CAGR of 11.57% during the forecast period (2026-2031). This report is Segmented by Cancer Type (Breast Cancer, Blood Cancer, Lung Cancer, Brain Cancer, Colorectal Cancer, and More), Application (Autologous Stem-Cell Transplant and Allogeneic Stem-Cell Transplant), Stem-Cell Source (Bone Marrow, Peripheral Blood and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Cancer Stem Cells Market Trends and Insights

Rising Cancer Incidence and Supportive Legislation

Global oncology caseloads are climbing, intensifying demand for therapies that eradicate the small, relapse-driving cancer stem-cell pool. Policymakers now streamline regulatory pathways: the FDA Modernization Act has removed certain animal-testing requirements, accelerating iPSC adoption in oncology. In Europe, the EMA’s advanced-therapy pilot cuts review fees for academic developers and provides continuous scientific guidance. Japan’s fast-track scheme for regenerative medicine is expected to green-light the first iPSC-based cancer therapy within the next year, underscoring global regulatory convergence. These shifts collectively boost adoption prospects and elevate the cancer stem cells market trajectory.

Escalating R&D Spending & Public-Private Funding

Governments and investors increasingly funnel capital into translational programmes. Japan’s ¥110 billion allocation to regenerative medicine finances more than 60 iPSC oncology trials worldwide. In the United States, the Reagan-Udall Foundation highlights gene-therapy overlaps with stem-cell biology, galvanising funding for multimodal regimens. Venture capital now targets AI-enhanced discovery engines that profile cancer stem-cell heterogeneity at single-cell depth, signalling strong confidence in technology-enabled platforms.

High Therapy Cost and Reimbursement Uncertainty

CAR-T procedures can top USD 1 million per patient, a benchmark that frames payer hesitancy for emerging cancer stem-cell interventions. Access remains limited: fewer than 20% of eligible U.S. patients receive approved cell and gene therapies, often due to reimbursement delays. Medicare’s national coverage determination for stem-cell transplantation clarifies criteria but remains disease-specific, leaving newer indications unfunded. Emerging markets confront even sharper affordability gaps, stalling broad uptake across the cancer stem cells market.

Other drivers and restraints analyzed in the detailed report include:

• Rapid Adoption of Advanced Cell-Isolation/3-D Culture Platforms
• AI-Driven Single-Cell Multi-Omics Accelerating CSC Target Discovery
• Ethical / Regulatory Complexity Around Manipulating Human Stem Cells

Segment Analysis

Breast cancer contributed 26.05% of revenue in 2025, the single-largest slice of the cancer stem cells market share. The segment benefits from high global prevalence and robust biomarker pipelines. AI-guided redox-signature assays now stratify patients by likely immunotherapy or chemotherapy benefit, tightening the fit between treatment and tumour biology. Triple-negative breast cancer trials evaluating CAR-modified cells and checkpoint inhibitors seek to curb aggressive, stem-cell-driven relapse.

Lung cancer represents the fastest-growing slice with a 12.41% CAGR, propelled by advances in micro-environment targeting that improve stem-cell homing and persistence. Blood cancers sustain material volumes thanks to entrenched transplantation protocols, while glioblastoma programmes test magnetic hyperthermia to eradicate resistant stem-cell niches. Pancreatic investigations, including claudin18.2-CAR-T case reports showing complete remission, highlight the breadth of innovation. Together, these trends reinforce diversified demand across the cancer stem cells market.

Complete Report Scope:

• By Cancer Type
  • Breast Cancer
  • Blood Cancer
  • Lung Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Liver Cancer
  • Other Cancer Types
• By Application
  • Autologous Stem-Cell Transplant
  • Allogeneic Stem-Cell Transplant
• By Stem-Cell Source
  • Bone Marrow
  • Peripheral Blood
  • Umbilical Cord Blood
  • Induced Pluripotent Stem Cells (iPSCs)
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 37.12% share in 2025, anchored by the FDA’s increasingly supportive stance exemplified by Ryoncil’s approval and by Medicare reimbursement frameworks that codify coverage for several transplant modalities. Academic-industry ecosystems leverage AI for single-cell analytics, enhancing trial design and accelerating bench-to-bedside translation. Decentralised manufacturing partnerships, such as the Galapagos-Blood Centers of America network, shrink delivery timelines, reinforcing regional dominance.

Asia Pacific is on track for a 13.05% CAGR, catalysed by Japan’s regulatory fast-track and capital spending exceeding ¥110 billion, which underpin more than 60 iPSC-based oncology trials. Local giants are erecting dedicated cGMP sites to meet future demand, while China’s regulatory reforms widen trial pipelines despite ongoing IP-protection challenges. Regional collaborations between academic centres and biotechs align well with the precision-oncology paradigm dominating the cancer stem cells market.

Europe benefits from the EMA’s advanced-therapy framework, though multi-country compliance still lengthens time to market. The approval of Casgevy, a CRISPR-edited stem-cell therapy, validates complex gene-editing modalities and sets safety benchmarks. The T2EVOLVE consortium pushes for streamlined CAR-T regulation to sustain competitiveness. Emerging Middle-East programmes, such as Saudi Arabia’s Cancer BioShield, and Mexico’s evolving cell-therapy rules, signal a widening global footprint.

List of Companies Covered in this Report:

• Thermo Fisher Scientific
• MerckKGaA
• Bio-Techne
• LonzaGroupAG
• MiltenyiBiotec
• PromoCellGmbH
• MacroGenicsInc.
• FUJIFILMIrvineScientific
• AcceGen
• CelprogenInc.
• ATCC
• STEMCELLTechnologiesInc.
• CorningInc.
• BDBiosciences
• QIAGENN.V.
• Cytiva
• SartoriusAG
• Advanced Cell Diagnostics
• BeckmanCoulter Life Sciences
• RocheDiagnostics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support